Singapore soldier dies after being found unconscious at military base swimming pool
Singapore's Ministry of Defence (Mindef) said the soldier was discovered around 7.15am and appeared to have been training alone before the incident. Immediate medical aid was provided, including cardiopulmonary resuscitation (CPR) and the use of an automated external defibrillator (AED).
The Singapore Police Force and the Singapore Civil Defence Force (SCDF) were alerted, and the serviceman was rushed to Changi General Hospital by ambulance. Resuscitation attempts continued during transport and upon arrival, but he was pronounced dead at 7.44am.
In a statement, Mindef said, 'The Ministry of Defence and the SAF extend their deepest condolences to the family of the late serviceman. We are also rendering assistance to the family during this time of grief.'
Hendon Camp is located in the eastern part of Singapore and is known as the base for the SAF's elite Commando unit.
Further details have not been released.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 days ago
- The Star
Singapore-based cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
SINGAPORE: Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium-sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targetted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. - The Straits Times/ANN
Malay Mail
4 days ago
- Malay Mail
Singapore soldier dies after being found unconscious at military base swimming pool
SINGAPORE, Aug 9 — A regular serviceman in the Singapore Armed Forces (SAF) has died after being found unconscious at a swimming pool inside Hendon Camp, a military base in Singapore, today. Singapore's Ministry of Defence (Mindef) said the soldier was discovered around 7.15am and appeared to have been training alone before the incident. Immediate medical aid was provided, including cardiopulmonary resuscitation (CPR) and the use of an automated external defibrillator (AED). The Singapore Police Force and the Singapore Civil Defence Force (SCDF) were alerted, and the serviceman was rushed to Changi General Hospital by ambulance. Resuscitation attempts continued during transport and upon arrival, but he was pronounced dead at 7.44am. In a statement, Mindef said, 'The Ministry of Defence and the SAF extend their deepest condolences to the family of the late serviceman. We are also rendering assistance to the family during this time of grief.' Hendon Camp is located in the eastern part of Singapore and is known as the base for the SAF's elite Commando unit. Further details have not been released.
Malay Mail
4 days ago
- Malay Mail
Singapore at increased risk of chikungunya as cases double in 2025, health agency warns
SINGAPORE, Aug 9 — Singapore is facing an increased risk of chikungunya transmission as the number of reported cases this year more than doubles compared to last year, the country's Communicable Diseases Agency (CDA) said yesterday. From January to August 2, 17 chikungunya cases were confirmed, surpassing the eight cases recorded in the same period last year and already exceeding the total 15 cases reported throughout 2024, according to CDA's weekly infectious disease bulletin, as cited by Singapore-based media organisation CNA. The presence of Aedes mosquitoes — the primary vector for chikungunya — and travellers carrying the virus are key factors in the potential spread of the disease, the agency explained. Of the 16 cases reported by the end of July, 13 involved individuals who had recently travelled to regions with chikungunya outbreaks. The remaining three local cases were isolated and showed no epidemiological links. Despite the rise in cases, the current numbers remain far lower than previous major outbreaks in Singapore. In 2008, Singapore recorded 718 chikungunya infections, which dropped sharply in subsequent years. Another surge occurred in 2013, with 1,059 cases reported, including 48 imported infections, highlighting the country's vulnerability to imported mosquito-borne diseases when local Aedes mosquito populations are present. CDA said it is closely monitoring the situation and will consider additional public health measures if new data indicate an increased risk to Singapore's population. Chikungunya, transmitted by infected Aedes mosquitoes, causes symptoms similar to dengue — such as fever, rash, headache, and joint pain. However, the joint pain associated with chikungunya can persist for weeks or months, leading to significant discomfort and disability, explained Professor Ooi Eng Eong, deputy director of the Emerging Infectious Diseases programme at Duke-NUS Medical School. 'Although chikungunya is not as life-threatening as dengue, it can be very debilitating,' he reportedly said to CNA.
